Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - United Therapeutics Corporation $ in Millions |
1 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2022
USD ($)
| ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Total anticipated cash flows | $ 722.3 | [1] | ||||
| R&D Services and License | Over Time | ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Progress Measure | Ratably | |||||
| Recognition Period | Aug 2021 - Oct 2021 | |||||
| Next-Gen R&D Services | Over Time | ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Anticipated Revenue Allocation | $ 10.0 | |||||
| Progress Measure | Input | |||||
| Recognition Period | % of completion of costs | |||||
| Manufacturing Services and Product Sales | Point In Time | ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Anticipated Revenue Allocation | $ 712.3 | [2] | ||||
| Recognition Period | Transfer of control | [2] | ||||
| Manufacturing Services | ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Total anticipated cash flows | $ 722.3 | |||||
| ||||||